Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
about
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingSurvival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersOvarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionThe Consequences of a BRCA Mutation in WomenRisk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriersFeasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.Understanding the needs of women considering risk-reducing salpingo-oophorectomy.Potential role of coregistered photoacoustic and ultrasound imaging in ovarian cancer detection and characterization.Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Current strategies for the prevention of breast cancerA Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerAcceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriersLocal therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian CancerClinical management of hereditary breast cancer syndromes.Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.Genome-wide association studies of cancer.Translational advances regarding hereditary breast cancer syndromes.Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagPrevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.Ingredients for success: a familial cancer clinic in an oncology practice setting.Ovarian cancer risk after salpingectomy: a nationwide population-based study.Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriersThe risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndromeA clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges.Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Breast cancer in young womenAddressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutationsIn their own words: treating very young BRCA1/2 mutation-positive women with care and caution.Fertility preservation and breast cancer: a review
P2860
Q24632270-4AABB398-1E53-46DD-B31F-4D9A31DE7559Q24654487-2F21E198-4967-4650-8BAD-80FBDA79AF37Q26744525-82C7C9E4-0B5D-43CB-A86E-E64E57119046Q26777891-5DA9F63E-1B6A-4F6F-ACC3-3BA0CFC07D1FQ27003935-0B6C1A90-1370-412C-92CD-5AD3F5343C53Q27316521-E39EC568-6777-4B7B-95CC-CE69C4B3CD38Q30419497-23966C98-13D6-4E32-89A1-E075676DBC8AQ30477398-65E5E49A-0987-4D31-A7D9-0F8859BCB578Q33563963-DE130B10-25A9-4772-A343-74C4130703A1Q33564013-C7690FDC-7070-4CAB-9AF7-A14337C25479Q33599463-24062FC1-A1E2-4C34-993D-242CB9F9AFD5Q33606561-6E6C643F-A164-43A3-87F5-03C45707780CQ33668934-2427DEF6-8EE4-48CB-BC51-6586AD183160Q33723561-827D5252-4F2A-40DE-B4FC-D5EFA4D08F7DQ33823472-A07B40DC-12B1-4545-9970-7E7EBCE1F7B6Q34114943-C6C69AE3-A20E-45FC-BBC9-D90E1C95588BQ34126089-05D3BFAC-6E10-4AB5-A984-5E94683BFF54Q34135443-1908C5B9-247B-4A19-8F41-C73CAEEEFE1AQ34152848-D9494CC8-2E1A-4539-A91D-89FBBC5B0568Q34167563-CCD43FDD-E1D1-4413-8088-A2A2EE0ACC1FQ34172655-81CEE764-2AB2-4711-BBC0-7F18819E943FQ34193988-F8171ED1-1C33-466C-A3F8-7A270E624F0FQ34263162-EBE459DB-89D8-4DA2-ACE3-06AA2B230EA8Q34327275-8CC2FB49-70C2-460E-9A3E-D76B324A09F8Q34354159-6B34C660-8058-47BF-9085-073774D1D420Q34421019-E0E8D6C6-107F-4F41-A323-57C86680FD22Q34459715-E95B8DA4-54E0-44A3-8FF7-42147610CCC0Q34460052-F066298D-7F70-4D80-B712-8DF3DB46FBD2Q34475484-67BE7CE3-64DE-4561-A4D8-1D8483BDB331Q34481713-DE9C37A3-CC0F-4A23-B57F-C31798694D51Q34527229-131CA435-B933-45FE-A42F-0B198D7D091FQ34600647-CB31A55F-504A-486D-B938-83C28F68A695Q34856782-B2660752-B262-4650-AEDF-1806A29B3CD7Q34977063-C73A714A-011B-4BD9-96EA-04688C9CC3CDQ34989073-ABD87E74-FE71-4DEF-A05A-78BFC04391C7Q35007815-DCB0827C-7B80-418C-AEF1-317CE436BCACQ35019634-62F5F641-FDC7-4310-931F-4755B9BC17B3Q35100315-873B9A2C-9A1F-457E-B55A-CEDE1A5F5BD2Q35105959-E5E9AB7B-99F2-4E9C-8C29-F53F3325668FQ35106163-846A9D58-B1F3-4B89-A586-0D24FCAA84E0
P2860
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@ast
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@en
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@nl
type
label
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@ast
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@en
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@nl
prefLabel
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@ast
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@en
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@nl
P2093
P2860
P50
P356
P1476
Risk-reducing salpingo-oophore ...... ulticenter, prospective study.
@en
P2093
Clifford Hudis
Ellen Matloff
Henry Lynch
Joanne L Blum
Johanna Lee
Judy E Garber
Mary B Daly
Paul Sabbatini
Richard R Barakat
Tara M Friebel
P2860
P304
P356
10.1200/JCO.2007.13.9626
P407
P50
P577
2008-02-11T00:00:00Z